Valuation: Axogen, Inc.

Market Cap 2.47B 2.13B 2.02B 1.83B 3.43B 236B 3.45B 23.97B 9.22B 120B 9.29B 9.09B 380B P/E 2026 *
-94.2x
P/E 2027 * 703x
Enterprise Value 2.47B 2.13B 2.02B 1.83B 3.43B 236B 3.45B 23.97B 9.22B 120B 9.29B 9.09B 380B EV / Sales 2026 *
8.85x
EV / Sales 2027 * 7.37x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week-12.68%
Current month-16.94%
1 month-12.26%
3 months-1.95%
6 months+30.36%
Current year+28.81%
1 week 39.62
Extreme 39.62
48.1
1 month 39.62
Extreme 39.62
52.91
Current year 27.54
Extreme 27.54
52.91
1 year 15.27
Extreme 15.2701
52.91
3 years 3.45
Extreme 3.45
52.91
5 years 3.45
Extreme 3.45
52.91
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 2024-08-08
Director of Finance/CFO 42 2025-05-11
Chief Operating Officer 65 2025-01-09
Director TitleAgeSince
Director/Board Member 65 2016-08-31
Director/Board Member 58 2019-05-14
Chairman 70 2024-08-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Director

-3,500 0.0065%
8/11/26 Exercice

Director

40,059 0.0745%
8/10/26 Exercice

Compliance Officer

202,500 0.3767%
Change 5-day change 1-year change 3-year change Capi.($)
+0.60%-12.68%+156.92%+666.55% 2.47B
+0.11%-0.65%+27.19%+19.36% 225B
-0.30%-3.62%+5.31%-20.72% 141B
+1.10%+0.67%-17.91%+21.95% 130B
+2.75%-10.08%-58.15%-19.21% 62.29B
+2.09%+1.45%-18.05%-13.51% 49.39B
+1.23%-6.15%+8.77%+15.31% 48.63B
-0.45%-2.61%+19.22%+29.53% 41.42B
-0.59%-0.25%+38.24%+52.80% 40.12B
+1.89%-4.41%-19.20%+49.15% 31.23B
Average +1.11%-4.17%+14.23%+80.12% 77.21B
Weighted average by Cap. +0.91%-2.43%+3.33%+12.59%

Financials

2026 *2027 *
Net sales 280M 241M 228M 207M 388M 26.71B 390M 2.71B 1.04B 13.59B 1.05B 1.03B 42.94B 336M 289M 274M 248M 466M 32.07B 468M 3.25B 1.25B 16.31B 1.26B 1.23B 51.55B
Net income -24.35M -20.98M -19.87M -18.01M -33.78M -2.33B -33.95M -236M -90.74M -1.18B -91.46M -89.45M -3.74B 3.04M 2.62M 2.48M 2.25M 4.22M 291M 4.24M 29.49M 11.34M 148M 11.43M 11.18M 467M
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
26-09-11 US$42.16 +0.74% 3,477,622
26-09-10 US$41.85 -11.47% 3,793,272
26-09-09 US$47.27 +1.24% 728,798
26-09-08 US$46.69 -3.29% 541,493
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
42.16USD
Average target price
53.90USD
Spread / Average Target
+27.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!